Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALNY Alnylam Pharmaceuticals

Closed 12-18 16:00:00 EST

396.04

+3.94

+1.00%

盘后396.04

+0.000.00%

17:40 EST

High404.19	Low391.51	Vol1.71M
Open394.49	D1 Closing392.10	Amplitude3.23%
Mkt Cap52.32B	Tradable Cap49.96B	Total Shares132.11M
T/O682.57M	T/O Rate1.36%	Tradable Shares126.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALNY","market":"US","secType":"STK","nameCN":"Alnylam Pharmaceuticals","latestPrice":396.04,"timestamp":1766091600000,"preClose":392.1,"halted":0,"volume":1714954,"hourTrading":{"tag":"盘后","latestPrice":396.04,"preClose":396.04,"latestTime":"17:40 EST","volume":170589,"amount":67560096.87,"timestamp":1766097654867},"delay":0,"floatShares":126154848,"shares":132113818,"eps":0.329855,"marketStatus":"Closed","change":3.94,"latestTime":"12-18 16:00:00 EST","open":394.49,"high":404.19,"low":391.51,"amount":682571002.38204,"amplitude":0.032339,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.329855,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766134800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1085630400000,"exchange":"NASDAQ","adjPreClose":392.1,"preHourTrading":{"tag":"盘前","latestPrice":397.11,"preClose":392.1,"latestTime":"09:28 EST","volume":321,"amount":127164.49025999999,"timestamp":1766068101075},"postHourTrading":{"tag":"盘后","latestPrice":396.04,"preClose":396.04,"latestTime":"17:40 EST","volume":170589,"amount":67560096.87,"timestamp":1766097654867},"volumeRatio":1.258343,"impliedVol":0.506,"impliedVolPercentile":0.8},"requestUrl":"/m/hq/s/ALNY/tweets","defaultTab":"tweets","newsList":[{"id":"2592903119","title":"Peptidream And Alnylam Announce Achievement Of Key Milestone In Sirna Conjugate Discovery Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2592903119","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592903119?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:20","pubTimestamp":1766060421,"startTime":"0","endTime":"0","summary":"Dec 18 (Reuters) - PeptiDream Inc <4587.T>::*PEPTIDREAM AND ALNYLAM ANNOUNCE ACHIEVEMENT OF KEY MILESTONE IN SIRNA CONJUGATE DISCOVERY COLLABORATION DEMONSTRATING PEPTIDE-LIGAND MEDIATED TARGETED SIRN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nRSD9LhvD0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","LU0889565916.HKD","LU0320765992.SGD","BK4585","ALNY","BK4548","LU0882574055.USD","BK4139","LU0109394709.USD","BK4588"],"gpt_icon":0},{"id":"2592190845","title":"PeptiDream Achieves Preclinical Milestone in siRNA Delivery Collaboration with Alnylam","url":"https://stock-news.laohu8.com/highlight/detail?id=2592190845","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592190845?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:00","pubTimestamp":1766059255,"startTime":"0","endTime":"0","summary":"PeptiDream Inc. announced the achievement of a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals, Inc. Under the terms of the agreement, PeptiDream will receive an undisclosed milestone payment from Alnylam and remains eligible for additional development, regulatory, and commercial milestone payments, as well as low-to-mid single-digit royalties on sales of any resulting Alnylam products. The collaboration, initiated in 2021, focuses on developing peptide-siRNA conjugates for targeted RNAi therapeutics delivery to tissues beyond the liver.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PeptiDream Inc. published the original content used to generate this news brief via Business Wire  on December 18, 202","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDLz4cx3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","BK4588","LU0109394709.USD","LU0114720955.EUR","ALNY","BK4139","LU0882574055.USD","BK4548","BK4585","LU0889565916.HKD"],"gpt_icon":0},{"id":"2592594908","title":"From on-device AI to the 'girlfriend index,' trading ideas from the research firm that nailed 2025's investment themes","url":"https://stock-news.laohu8.com/highlight/detail?id=2592594908","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592594908?lang=en_us&edition=fundamental","pubTime":"2025-12-18 19:52","pubTimestamp":1766058720,"startTime":"0","endTime":"0","summary":"Citrini Research urges investors to stay open-minded in the year ahead. Citrini Research says companies aren't getting enough credit by investors for shaving jobs.Be open to \"maybe,\" says a research firm whose founder who nailed diet drugs and AI themes early.\"While there's a laundry list of things I wish I had done differently since the market bottomed in October 2022, I know that the only reason I've more than tripled my money since then is because I was open to maybe,\" says Citrini Research in its just-released trades for 2026. \"Maybe the hyperscalers will actually be fine if rates are higher for longer. Maybe AI isn't the next fad investors immediately get burned on.\". Here are some of Citrini's 26 ideas for 2026, starting with a basket of companies overlooked in the rush to invest in big AI players.\"If 2026 is the year we see AI-driven head count reductions and productivity gains, one might expect that there would be some degree of anticipation of this AI-shift in the share price ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLY","LU0348723411.USD","WPP","ARWR","BP","LU0256863811.USD","TSYW.SI","CRSR","LU0234570918.USD","LU0203201768.USD","AVY","RL","HPQ","OMC","LU0096364046.USD","ONDS","ADI","MACW.SI","TSLA","MU","LU0231203729.USD","KTOS","SG9999018865.SGD","WVE","AI","LU1301847155.USD","ALNY","BK4534","MOH","SG9999002224.SGD","CTSH","BAH","LU0385154629.USD","LULU","QCOM","LU2083900584.USD","BK4533","OSCR","BK4598","AAPL","IBM","GIB","TGNA","IE00B775H168.HKD","AS","CNC","DELL","NXST","SBGI","LU1506573853.SGD"],"gpt_icon":0},{"id":"2592990467","title":"BRIEF-Alnylam To Invest $250 Million To Add Enzymatic Ligation Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990467","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990467?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:08","pubTimestamp":1765976896,"startTime":"0","endTime":"0","summary":"BRIEF-Alnylam To Invest $250 Million To Add Enzymatic Ligation Platform Dec 17 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O:ALNYLAM TO INVEST $250 MILLION TO ADD ENZYMATIC LIGATION PLATFORM TO U.S. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA9XHXBG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0320765992.SGD","BK4588","BK4548","LU0882574055.USD","LU0114720955.EUR","BK4585","ALNY","LU0889565916.HKD","BK4139"],"gpt_icon":0},{"id":"2592990937","title":"Alnylam Invests $250 Million to Expand RNAi Drug Manufacturing in Massachusetts","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990937","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990937?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:00","pubTimestamp":1765976447,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals Inc. has announced a $250 million investment to expand its manufacturing facility in Norton, Massachusetts. The expansion will add the industry's first fully dedicated, proprietary siRNA enzymatic-ligation manufacturing platform, significantly increasing production capacity and reducing costs. The 200,000 square foot facility, which opened in 2021, will support both clinical and commercial supply of siRNA oligonucleotide drug substances, accelerating Alnylam's growing pipeline of RNAi therapeutics. The new capabilities are expected to be fully operational by late 2027, further strengthening Massachusetts' position as a global leader in life sciences and creating high-quality jobs in the region.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDLbsqFN8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU0320765992.SGD","ALNY","LU0114720955.EUR","BK4585","BK4548","LU0109394709.USD","LU0889565916.HKD","BK4588","BK4139"],"gpt_icon":0},{"id":"2592998990","title":"Alnylam Pharmaceuticals Inc - New Capabilities Operational by Late 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2592998990","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592998990?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:00","pubTimestamp":1765976401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA9XHXBG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","LU0114720955.EUR","BK4585","LU0109394709.USD","LU0882574055.USD","ALNY","LU0889565916.HKD","BK4548","BK4139","BK4588"],"gpt_icon":0},{"id":"2592990626","title":"Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for Rnai Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990626","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990626?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:00","pubTimestamp":1765976401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA9XHXBG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","BK4548","LU0114720955.EUR","LU0882574055.USD","BK4139","BK4585","LU0889565916.HKD","BK4588","LU0320765992.SGD","ALNY"],"gpt_icon":0},{"id":"2591938696","title":"BRIEF-Alnylam Announces Health Canada Approval Of Amvuttra®","url":"https://stock-news.laohu8.com/highlight/detail?id=2591938696","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591938696?lang=en_us&edition=fundamental","pubTime":"2025-12-16 22:37","pubTimestamp":1765895845,"startTime":"0","endTime":"0","summary":"BRIEF-Alnylam Announces Health Canada Approval Of Amvuttra Dec 16 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O:ALNYLAM ANNOUNCES HEALTH CANADA APPROVAL OF AMVUTTRA (VUTRISIRAN), THE FIRST AND ONLY R","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nFWN3XM09T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4548","ALNY","LU0882574055.USD","LU0109394709.USD","LU0320765992.SGD","BK4588","BK4585","LU0889565916.HKD","LU0114720955.EUR"],"gpt_icon":0},{"id":"2591771984","title":"Alnylam Announces Health Canada Approval of Amvuttra® (Vutrisiran), the First and Only Rnai Therapeutic for the Treatment of Cardiomyopathy in Adult Patients With Attr Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2591771984","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591771984?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:01","pubTimestamp":1765890099,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nFWN3XM09T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4548","BK4588","LU0889565916.HKD","BK4139","BK4585","LU0114720955.EUR","LU0109394709.USD","LU0320765992.SGD","LU0882574055.USD","ALNY"],"gpt_icon":0},{"id":"2591988623","title":"Is Alnylam (ALNY) Using Nasdaq 100 Inclusion To Quietly Redefine Its Capital Allocation Playbook?","url":"https://stock-news.laohu8.com/highlight/detail?id=2591988623","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591988623?lang=en_us&edition=fundamental","pubTime":"2025-12-16 13:13","pubTimestamp":1765862029,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals recently reshaped its governance and capital structure, with two long-serving directors stepping down, a new independent director appointed, and a partial repurchase of US$34.4 million of its 1.00% convertible senior notes due 2027 at a total cost of US$51.9 million.\nThe company’s upcoming inclusion in the Nasdaq 100 Index on December 22, alongside evolving board expertise and debt reduction, could broaden its investor base and refine its long-term growth profile in...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/is-alnylam-alny-using-nasdaq-100-inclusion-to-quietly-redefi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/is-alnylam-alny-using-nasdaq-100-inclusion-to-quietly-redefi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4588","BK4548","BK4139","ALNY","LU0109394709.USD","LU0889565916.HKD","LU0114720955.EUR","LU0882574055.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2591181621","title":"Alnylam Pharmaceuticals Is Maintained at Market Perform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2591181621","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591181621?lang=en_us&edition=fundamental","pubTime":"2025-12-16 04:52","pubTimestamp":1765831920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 15, 2025 15:52 ET (20:52 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY","BK4139","BK4588","LU0889565916.HKD","BK4585","BK4548","LU0114720955.EUR","LU0109394709.USD","LU0882574055.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2591164307","title":"Alnylam Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $351 From $370","url":"https://stock-news.laohu8.com/highlight/detail?id=2591164307","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591164307?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:57","pubTimestamp":1765799864,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL0F0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4548","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","ALNY","BK4139","LU0882574055.USD","BK4588","LU0114720955.EUR","BK4585"],"gpt_icon":0},{"id":"2591658865","title":"Walmart was too late for a Nasdaq-100 spot - but these 6 stocks made the cut","url":"https://stock-news.laohu8.com/highlight/detail?id=2591658865","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591658865?lang=en_us&edition=fundamental","pubTime":"2025-12-14 00:04","pubTimestamp":1765641840,"startTime":"0","endTime":"0","summary":"Strategy maintained its place in the tech-heavy index, but Lululemon and Trade Desk are among the companies getting the boot. Walmart transferred to the Nasdaq too late to be eligible for the Nasdaq-100's annual reconstitution.Six companies will join the Nasdaq-100 later this month - but not Walmart, which switched its listing away from the New York Stock Exchange too late to qualify for a spot in the tech-heavy index.While some thought Strategy  might lose its spot due to a potentially more stringent look at whether the cryptocurrency holding company and software provider should actually be considered a nonfinancial company, it kept its place.Alnylam, which uses RNA in biotechnology, was the largest eligible candidate for a spot, according to a MarketWatch review of Nasdaq-listed companies as of Nov. 28; its market cap was about $60 billion then. Real-estate investment trusts like Equinix  aren't eligible for entry, even though the data-center provided has a larger valuation.There are","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4571","LU1244550494.USD","CDW","3NVD.UK","NVDY","NVIW.SI","FER","2NVD.UK","MACW.SI","SG9999014906.USD","STRK","SNVD.UK","MPWR","ON","NVD2.UK","TTD","BIIB","LU0823414551.USD","NVDS.UK","USJW.SI","LU0053666078.USD","LU2213496289.HKD","ALNY","NVDD","INSM","IE0004445015.USD","EQIX","NVD","NVDX","BK4503","NVD3.UK","LU1228905037.USD","NVDU","WMT","NQmain","GFS","LU0068578508.USD","LU0957808578.USD","NVDS"],"gpt_icon":1},{"id":"2591800456","title":"Nasdaq Says Biogen, CDW Corporation, Globalfoundries, Lululemon Athletica, On Semiconductor, Trade Desk Will Be Removed From Nasdaq 100 Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2591800456","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591800456?lang=en_us&edition=fundamental","pubTime":"2025-12-13 09:20","pubTimestamp":1765588842,"startTime":"0","endTime":"0","summary":"Dec 12 (Reuters) - Nasdaq Inc ::*NASDAQ INC - ANNOUNCES RECONSTITUTION OF NASDAQ-100 INDEX EFFECTIVE DEC 22*NASDAQ INC: SIX COMPANIES WILL BE ADDED TO NASDAQ 100 INDEX*NASDAQ INC:  BIOGEN, CDW CORPORA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"379c269ef09dde4ff2ea787d7ec186f0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251213:nRSD2Snvr3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","LU2089985449.USD","LU1854104046.USD","LU1670628061.USD","LU2272731782.SGD","MPWR","BK4588","LU0444971666.USD","BK4532","LU1861219969.SGD","LU2360107325.USD","LU1548497426.USD","LU0353189680.USD","LU1046421795.USD","GFS","LU1642822529.SGD","ALNY","LU0320765992.SGD","LU0353189763.USD","LU1992135399.USD","LULU","LU1670627923.USD","LU1235294995.USD","BK4141","LU1720051108.HKD","LU2272731600.USD","BK4512","LU0882574055.USD","LU0109394709.USD","LU1992135472.HKD","LU1852331112.SGD","BK4528","BK4605","LU2322448791.USD","CDW","LU2290526834.HKD","LU1496350502.SGD","LU0708995401.HKD","LU0348723411.USD","LU0056508442.USD","IE00B894F039.SGD","LU1861215975.USD","IE00BN0W2W23.USD","LU1035773651.USD","LU2360107168.USD","TTD","LU1861214812.USD","ON"],"gpt_icon":1},{"id":"2591680426","title":"Seagate, Western Digital And Other Four Companies Will Be Added To Nasdaq 100 Index, While Lululemon, ON Semi, Trade Desk And Other Three Companies Will Be Removed","url":"https://stock-news.laohu8.com/highlight/detail?id=2591680426","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591680426?lang=en_us&edition=fundamental","pubTime":"2025-12-13 09:15","pubTimestamp":1765588542,"startTime":"0","endTime":"0","summary":"","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"379c269ef09dde4ff2ea787d7ec186f0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251213:nFWN3XI16U:3","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Seagate, Western Digital And Other Four Companies Will Be Added To Nasdaq 100 Index, While Lulule...","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999014013.SGD","LU0053671581.USD","LU1992135399.USD","LU0274383776.USD","LU0353189680.USD","LU2298322129.HKD","LU1861215975.USD","IE00BN0W2T93.GBP","LU1861214812.USD","BK4139","TTD","LU0708995401.HKD","IE00BN0W2V16.EUR","LU1720051108.HKD","LU1548497426.USD","LU1267930730.SGD","LU2272731782.SGD","LU0476273544.USD","LU0320765992.SGD","LU1069347547.HKD","LU2290526834.HKD","IE00BD6J9T35.USD","FER","LU1992135472.HKD","LU1854103824.USD","LU2360107325.USD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2322448791.USD","LU2931357623.SGD","BK4141","LU0348723411.USD","LU1861220033.SGD","SG9999014005.SGD","LU1854104046.USD","BIIB","BK6515","ON","IE00BZ199S13.USD","BK4009","ALNY","SG9999014039.USD","LU2210149790.SGD","LU2087625088.SGD","LU0314104364.USD","LU0724618433.USD","NQmain","LU2210150020.SGD","LU1720051017.SGD","BK4202","NDAQ","LU1815336760.USD","IE00B64PRP62.GBP","LU1978683503.SGD","LU1861219969.SGD","SG9999014021.USD","GFS","LU0320765059.SGD","CDW","INSM","IE00B19Z9P08.USD","BK4533","IE00BFMHRM44.USD","BK4585","LU0234570918.USD","LU1642822529.SGD","BK4528","LU2272731600.USD","BK4613","LU0006061336.USD","WDC","LU0109394709.USD","LU0114720955.EUR","LU0056508442.USD","BK4532","BK4588","LU0109391861.USD","MPWR","LU2357305700.SGD","IE00B19Z9Z06.USD","LU2360107168.USD","LU0353189763.USD","BK6058","BK4504","BK4605","LU0444971666.USD","LU2272731865.HKD","LU1852331112.SGD","LU1496350502.SGD","IE00BN0W2W23.USD","LU2095319765.USD","LULU","LU0957808578.USD","BXE.SI","BK4548","LU1235294995.USD","LU0672654240.SGD","BK4023","LU0889565916.HKD","LU2250418816.HKD","BK4512","IE00BKPKM429.USD","LU0882574055.USD","LU2360106780.USD","BK4170","STX","LU2322448957.HKD","LU0823411888.USD","LU1823568750.SGD","IE00B894F039.SGD","LU1035773651.USD","LU1046421795.USD","BK4112","LU2089985449.USD","LU0081259029.USD","LU0444973449.USD","LU2473716301.USD","LU0124384867.USD"],"gpt_icon":1},{"id":"2591680250","title":"Nasdaq Inc: Alnylam Pharmaceuticals, Ferrovial, Insmed, Monolithic Power Systems, Seagate Technology, Western Digital Will Be Added to Nasdaq 100 Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2591680250","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591680250?lang=en_us&edition=fundamental","pubTime":"2025-12-13 09:09","pubTimestamp":1765588170,"startTime":"0","endTime":"0","summary":"","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251213:nFWN3XI16U:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999014039.USD","LU1823568750.SGD","BK4588","LU0053671581.USD","LU2272731782.SGD","LU1992135472.HKD","LU1815336760.USD","WDC","BK4141","FER","NDAQ","LU1046421795.USD","BK4585","LU2360106780.USD","IE00BKPKM429.USD","LU0203345920.USD","LU1861220033.SGD","LU2250418816.HKD","MPWR","LU2087625088.SGD","IE00BN0W2T93.GBP","LU0081259029.USD","LU0444973449.USD","LU0476273544.USD","LU1235294995.USD","LU2089985449.USD","STX","LU1267930730.SGD","LU2931357623.SGD","IE00BGHQF748.EUR","LU1670628061.USD","LU0114720955.EUR","LU0006061336.USD","BK4170","IE00BN0W2W23.USD","ALNY","LU0353189763.USD","LU0672654240.SGD","LU0889565916.HKD","LU2473716301.USD","LU1852331112.SGD","IE00BN0W2V16.EUR","IE00BD6J9T35.USD","INSM","LU2322448791.USD","LU2322448957.HKD","LU2272731865.HKD","LU0320765992.SGD","LU2272731600.USD","LU1642822529.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2590159555","title":"BRIEF-Alnylam Announces Partial Repurchase Of 1.00% Convertible Senior Notes Due 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2590159555","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590159555?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:48","pubTimestamp":1765457307,"startTime":"0","endTime":"0","summary":"BRIEF-Alnylam Announces Partial Repurchase Of 1.00% Convertible Senior Notes Due 2027Dec 11 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O:ALNYLAM ANNOUNCES PARTIAL REPURCHASE OF 1.00% CONVERTIBLE SEN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA8WMVK5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4548","ALNY","LU0882574055.USD","LU0109394709.USD","LU0320765992.SGD","BK4588","BK4585","LU0889565916.HKD","LU0114720955.EUR"],"gpt_icon":0},{"id":"2590421518","title":"Alnylam Repurchases $34.4 Million of 2027 Convertible Notes for $51.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2590421518","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590421518?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:00","pubTimestamp":1765454436,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals Inc. has announced it has entered into privately negotiated agreements to repurchase approximately $34.4 million in aggregate principal amount of its 1.00% Convertible Senior Notes due 2027 for a total cost of about $51.9 million, including accrued and unpaid interest. The final repurchase price will be partly determined based on the daily volume-weighted average price of Alnylam's common stock over a specified measurement period starting December 11, 2025. After the repurchases, about $362.8 million of the notes will remain outstanding. The company's previously established capped call transactions related to these notes will remain in effect.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceutical","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL3Z6XFr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","BK4585","BK4588","BK4139","LU0889565916.HKD","LU0882574055.USD","LU0320765992.SGD","BK4548","LU0109394709.USD","ALNY"],"gpt_icon":0},{"id":"2590518031","title":"Alnylam Pharmaceuticals Inc - to Repurchase $34.4 Mln Convertible Senior Notes for $51.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2590518031","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590518031?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:00","pubTimestamp":1765454402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA8WMVK5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","BK4548","LU0114720955.EUR","LU0320765992.SGD","LU0889565916.HKD","BK4139","ALNY","LU0109394709.USD","LU0882574055.USD"],"gpt_icon":0},{"id":"2590567097","title":"U.S. RESEARCH ROUNDUP-BioNTtech, GE Vernova, Synopsys","url":"https://stock-news.laohu8.com/highlight/detail?id=2590567097","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590567097?lang=en_us&edition=fundamental","pubTime":"2025-12-11 15:10","pubTimestamp":1765437037,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-BioNTtech, GE Vernova, SynopsysDec 11 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including BioNTech, GE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nL8N3XH0CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CQP","CHYM","ACAD","CRI","CAG","BAC","BTSG","TXG","AUB","BK4139","BK4581","CWST","U","AZO","CAT","CHWY","BK4566","LU0557290698.USD","BK4196","LU1720051108.HKD","ALSN","APP","LU2210149790.SGD","BKR","ACVA","CL","ANF","CVNA","DRI","BNTX","AR","CARG","CNM","AAOI","ARGX","LU0061474960.USD","WHD","LNG","BBIO","AEO","BMBL","ALNY","LU1043141123.HKD","CVX","GOOGL","ANAB","LU1934455277.USD","ADBE","BOOT","CMI"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.alnylam.com","stockEarnings":[{"period":"1week","weight":-0.0306},{"period":"1month","weight":-0.1486},{"period":"3month","weight":-0.1328},{"period":"6month","weight":0.2661},{"period":"1year","weight":0.5902},{"period":"ytd","weight":0.6663}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.52381,"avgChangeRate":0.037108},{"month":2,"riseRate":0.47619,"avgChangeRate":0.003609},{"month":3,"riseRate":0.47619,"avgChangeRate":-0.013154},{"month":4,"riseRate":0.380952,"avgChangeRate":-0.019703},{"month":5,"riseRate":0.619048,"avgChangeRate":0.04124},{"month":6,"riseRate":0.636364,"avgChangeRate":0.064494},{"month":7,"riseRate":0.681818,"avgChangeRate":0.106925},{"month":8,"riseRate":0.590909,"avgChangeRate":0.037005},{"month":9,"riseRate":0.545455,"avgChangeRate":0.034409},{"month":10,"riseRate":0.409091,"avgChangeRate":-0.042013},{"month":11,"riseRate":0.727273,"avgChangeRate":0.078577},{"month":12,"riseRate":0.454545,"avgChangeRate":0.005698}],"exchange":"NASDAQ","name":"Alnylam Pharmaceuticals","nameEN":"Alnylam Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alnylam Pharmaceuticals,ALNY,Alnylam Pharmaceuticals股票,Alnylam Pharmaceuticals股票老虎,Alnylam Pharmaceuticals股票老虎国际,Alnylam Pharmaceuticals行情,Alnylam Pharmaceuticals股票行情,Alnylam Pharmaceuticals股价,Alnylam Pharmaceuticals股市,Alnylam Pharmaceuticals股票价格,Alnylam Pharmaceuticals股票交易,Alnylam Pharmaceuticals股票购买,Alnylam Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction